KR20210022575A - 심장-특이적 표적화-펩티드 (ctp), 조성물, 및 그의 용도 - Google Patents

심장-특이적 표적화-펩티드 (ctp), 조성물, 및 그의 용도 Download PDF

Info

Publication number
KR20210022575A
KR20210022575A KR1020207036623A KR20207036623A KR20210022575A KR 20210022575 A KR20210022575 A KR 20210022575A KR 1020207036623 A KR1020207036623 A KR 1020207036623A KR 20207036623 A KR20207036623 A KR 20207036623A KR 20210022575 A KR20210022575 A KR 20210022575A
Authority
KR
South Korea
Prior art keywords
ctp
peptide
seq
xaa
cargo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207036623A
Other languages
English (en)
Korean (ko)
Inventor
말리하 자히드
Original Assignee
유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 filed Critical 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
Publication of KR20210022575A publication Critical patent/KR20210022575A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207036623A 2018-05-23 2019-05-22 심장-특이적 표적화-펩티드 (ctp), 조성물, 및 그의 용도 Ceased KR20210022575A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862675307P 2018-05-23 2018-05-23
US62/675,307 2018-05-23
US201862778033P 2018-12-11 2018-12-11
US62/778,033 2018-12-11
US201962811077P 2019-02-27 2019-02-27
US62/811,077 2019-02-27
PCT/US2019/033551 WO2019226785A1 (en) 2018-05-23 2019-05-22 Cardiac-specific targeting-peptide (ctp), compositions, and uses thereof

Publications (1)

Publication Number Publication Date
KR20210022575A true KR20210022575A (ko) 2021-03-03

Family

ID=68617073

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207036623A Ceased KR20210022575A (ko) 2018-05-23 2019-05-22 심장-특이적 표적화-펩티드 (ctp), 조성물, 및 그의 용도

Country Status (8)

Country Link
US (2) US20210206805A1 (https=)
EP (1) EP3811451A4 (https=)
JP (1) JP2021525246A (https=)
KR (1) KR20210022575A (https=)
CN (1) CN112512546A (https=)
AU (1) AU2019275044B2 (https=)
CA (1) CA3100943A1 (https=)
WO (1) WO2019226785A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210712A2 (en) 2019-04-10 2020-10-15 Coralluma Llc. Ir700 nanocompositions for cardiac therapies and applications
WO2021087037A1 (en) * 2019-10-29 2021-05-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Lung-specific targeting-peptide (ltp), compositions, and uses thereof
EP4531869A2 (en) * 2022-05-31 2025-04-09 Georgetown University Use of conjugates of microrna and cardiac targeting peptides for treating heart failure
AU2024314139A1 (en) 2023-06-20 2026-01-08 Kuva Labs Inc. Methods for magnetic resonance molecular imaging of nanoconstructs and uses thereof
ES2953301B2 (es) * 2023-09-25 2024-06-03 Univ Madrid Complutense Péptido para el tratamiento de enfermedades cardiacas
WO2025106145A1 (en) * 2023-11-13 2025-05-22 Mayo Foundation For Medical Education And Research Hybrid form of cardiac targeting peptide with increased serum stability and enhanced cardiomyocyte targeting

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063576A (en) * 1998-06-29 2000-05-16 University Of Utah Research Foundation Actin mutations in dilated cardiomyopathy, a heritable form of heart failure
EP2316468A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
RS91004A (sr) * 2002-04-15 2007-02-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education, Postupci za lečenje ileusa
JP2007505158A (ja) * 2003-05-21 2007-03-08 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 心肥大および心不全の処置としてのプロテインキナーゼＣ−μ（ＰＫＤ）の阻害
US8460658B2 (en) * 2003-10-10 2013-06-11 Alchemia Oncology Pty Limited Method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
WO2010033868A2 (en) * 2008-09-19 2010-03-25 Taligen Therapeutics, Inc. Ligand-specific non-antibody compounds that inhibit cr2 activation and methods of use thereof
AU2010305284A1 (en) * 2009-10-06 2012-05-03 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
US9249184B2 (en) * 2010-10-14 2016-02-02 University of Pittsburgh—of the Commonwealth System of Higher Education Cardiac-specific protein targeting domain
US10512691B2 (en) * 2012-04-23 2019-12-24 The Regents Of The University Of Michigan Systems and methods for targeted imaging and ablation of cardiac cells
EP2928502B1 (en) * 2012-12-05 2019-01-23 Ruprecht-Karls-Universität Heidelberg Conjugates of proteins and multivalent cell-penetrating peptides and their uses
WO2014093251A1 (en) * 2012-12-10 2014-06-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Engineered receptors and their use
US9550981B2 (en) * 2014-01-22 2017-01-24 University Of Washington Modified tafazzin proteins and methods of making and using the same
WO2018090042A1 (en) * 2016-11-14 2018-05-17 Renova Therapeutics, Inc. Methods of treating heart failure

Also Published As

Publication number Publication date
JP2021525246A (ja) 2021-09-24
WO2019226785A1 (en) 2019-11-28
EP3811451A1 (en) 2021-04-28
AU2019275044B2 (en) 2025-06-26
AU2019275044A1 (en) 2020-12-17
EP3811451A4 (en) 2022-04-06
CA3100943A1 (en) 2019-11-28
US20230406882A1 (en) 2023-12-21
WO2019226785A8 (en) 2020-06-18
US20210206805A1 (en) 2021-07-08
CN112512546A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
US20230406882A1 (en) Cardiac-specific targeting-peptide (ctp), compositions, and uses thereof
ES2525649T3 (es) Derivados peptídicos y su uso como vectores de moléculas en forma de conjugados
ES2822942T3 (es) Formulaciones de productos biológicos para instilación intravesical
US9249184B2 (en) Cardiac-specific protein targeting domain
EP3848055A1 (en) Compositions and methods for transport across the blood brain barrier
JP2022081521A (ja) 膀胱内注入用の生物製剤の処方
CN112969451A (zh) 使用α连接蛋白C端肽的纳米粒子制剂和方法
KR20200003889A (ko) C-말단 cdnf 및 manf 단편, 이를 포함하는 약학적 조성물 및 그 용도
WO2014059384A2 (en) ICAM-1 TARGETING ELPs
US20220315625A1 (en) Lung-specific targeting-peptide (ltp), compositions, and uses thereof
CA3003964A1 (en) Molecular probes for detecting gram-negative bacteria in vitro and in vivo
US20230144488A1 (en) Cell-penetrating peptide and use thereof
US20240197896A1 (en) Synthetic peptide shuttle agent bioconjugates for intracellular cargo delivery
EP2397151B1 (en) Treatment of vascular complications of diabetes
WO2017210693A1 (en) Protein polymer fusions for subcutaneous delivery of small molecules
WO2017147044A1 (en) Peptides and methods for treatment of neurodegenerative diseases
TW202003015A (zh) Ｃ端腦部多巴胺神經滋養因子（ｃｄｎｆ）及中腦星狀細胞－衍生之神經滋養因子（ｍａｎｆ）片段、包含彼之醫藥組成物及其用途
US11446365B2 (en) Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
JP2022521266A (ja) アミロイドペプチドバリアント
US20250177479A1 (en) Depsipeptide-based amphiphilic buliding block to inhibit protein-protein interactions, nanostructure comprised thereof and uses thereof
CN112020555A (zh) 肽及其应用
TW202509086A (zh) c－Met蛋白質結合肽複合物
CN120459058A (zh) 一种工程化细胞膜纳米颗粒及其制备方法和应用
JP2023533222A (ja) バソプレシン２受容体アンタゴニストペプチド及びその使用
CN115957295A (zh) 一类订书肽化合物在制备治疗肝纤维化药物中的应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000